Literature DB >> 24334652

Outcome measures in acute gout: a systematic literature review.

Nicola Dalbeth1, Cathy S Zhong, Rebecca Grainger, Dinesh Khanna, Puja P Khanna, Jasvinder A Singh, Fiona M McQueen, William J Taylor.   

Abstract

OBJECTIVE: Five core domains have been endorsed by Outcome Measures in Rheumatology (OMERACT) for acute gout: pain, joint swelling, joint tenderness, patient global assessment, and activity limitation. We evaluated instruments for these domains according to the OMERACT filter: truth, feasibility, and discrimination.
METHODS: A systematic search strategy for instruments used to measure the acute gout core domains was formulated. For each method, articles were assessed by 2 reviewers to summarize information according to the specific components of the OMERACT filter.
RESULTS: Seventy-seven articles and abstracts met the inclusion criteria. Pain was most frequently reported (76 studies, 20 instruments). The pain instruments used most often were 100 mm visual analog scale (VAS) and 5-point Likert scale. Both methods have high feasibility, face and content validity, and within- and between-group discrimination. Four-point Likert scales assessing index joint swelling and tenderness have been used in numerous acute gout studies; these instruments are feasible, with high face and content validity, and show within- and between-group discrimination. Five-point Patient Global Assessment of Response to Treatment (PGART) scales are feasible and valid, and show within- and between-group discrimination. Measures of activity limitations were infrequently reported, and insufficient data were available to make definite assessments of the instruments for this domain.
CONCLUSION: Many different instruments have been used to assess the acute gout core domains. Pain VAS and 5-point Likert scales, 4-point Likert scales of index joint swelling and tenderness and 5-point PGART instruments meet the criteria for the OMERACT filter.

Entities:  

Keywords:  GOUT; MEASUREMENT; OUTCOME; PAIN

Mesh:

Substances:

Year:  2013        PMID: 24334652      PMCID: PMC4217650          DOI: 10.3899/jrheum.131244

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  48 in total

1.  Piroxicam in treatment of acute gout high dose versus low dose.

Authors:  T Tumrasvin; U Deesomchok
Journal:  J Med Assoc Thai       Date:  1985-03

2.  Does colchicine work? The results of the first controlled study in acute gout.

Authors:  M J Ahern; C Reid; T P Gordon; M McCredie; P M Brooks; M Jones
Journal:  Aust N Z J Med       Date:  1987-06

3.  Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs.

Authors:  N Bellamy; W W Downie; W W Buchanan
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

4.  Use of tenoxicam in patients with acute gouty arthritis.

Authors:  E F Valdés
Journal:  Eur J Rheumatol Inflamm       Date:  1987

5.  Clinical experience with isoxicam in patients with acute gout.

Authors:  M A Fletcher; A G Wade
Journal:  Br J Clin Pract       Date:  1985-03

6.  Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect.

Authors:  G Katona; R Burgos-Vargas
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Evaluation of tenoxicam in rheumatology--clinical trial results in Argentina and Brazil.

Authors:  C A Barclay; C A Traballi
Journal:  Eur J Rheumatol Inflamm       Date:  1987

8.  Fentiazac in acute gouty arthritis.

Authors:  J Molina
Journal:  Clin Ther       Date:  1985       Impact factor: 3.393

9.  Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study.

Authors:  R Eberl; A Dunky
Journal:  Arzneimittelforschung       Date:  1983

10.  Flurbiprofen in the treatment of acute gout. A comparison with indomethacin.

Authors:  P L Lomen; L F Turner; K R Lamborn; M A Winblad; R L Sack; E L Brinn
Journal:  Am J Med       Date:  1986-03-24       Impact factor: 4.965

View more
  8 in total

Review 1.  Colchicine for acute gout.

Authors:  Bayden J McKenzie; Mihir D Wechalekar; Renea V Johnston; Naomi Schlesinger; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2021-08-26

2.  Efficacy and Safety of Qinpi Tongfeng Formula in the Treatment of Acute Gouty Arthritis: A Double-Blind, Double-Dummy, Multicenter, Randomized Controlled Trial.

Authors:  Yihua Fan; Wei Liu; Hang Lu; Jian Liu; Rui Wu; Jun Zhao; Aihua Wang; Xianheng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-12       Impact factor: 2.650

3.  High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: From a Southern Chinese Han Population.

Authors:  Wen Liu; Keshav Raj Sigdel; Ying Wang; Qun Su; Yan Huang; Yan Lin Zhang; Jie Chen; Lihua Duan; Guixiu Shi
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

4.  Alternate Warm and Cold Therapy (AWCT) on Uricemia, Sleep, Pain, Functional Ability, and Quality of Life (USPFQoL) in Patients with Gout: A Path Forward.

Authors:  Premalatha Paulsamy; Krishnaraju Venkatesan; ShadiaHamoud Alshahrani; Fazil Ahmad; Mohamed El-Sherbiny; Vani Manoharan; Kalaiselvi Periannan; RashaElsayed Ahmed; Kousalya Prabahar; Dawit Mamiru Teressa
Journal:  J Healthc Eng       Date:  2022-03-09       Impact factor: 2.682

5.  One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.

Authors:  Till Uhlig; Lars F Karoliussen; Joe Sexton; Tore K Kvien; Espen A Haavardsholm; Fernando Perez-Ruiz; Hilde Berner Hammer
Journal:  Arthritis Res Ther       Date:  2022-04-20       Impact factor: 5.606

Review 6.  The quality of systematic reviews of health-related outcome measurement instruments.

Authors:  C B Terwee; C A C Prinsen; M G Ricci Garotti; A Suman; H C W de Vet; L B Mokkink
Journal:  Qual Life Res       Date:  2015-09-07       Impact factor: 4.147

7.  What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.

Authors:  Sophi Tatlock; Katja Rüdell; Charlotte Panter; Rob Arbuckle; Leslie R Harrold; William J Taylor; Tara Symonds
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

8.  A systematic review finds Core Outcome Set uptake varies widely across different areas of health.

Authors:  Karen L Hughes; Mike Clarke; Paula R Williamson
Journal:  J Clin Epidemiol       Date:  2020-09-26       Impact factor: 6.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.